Actively Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Led by Merck Sharp & Dohme LLC · Updated on 2026-05-08
900
Participants Needed
41
Research Sites
366 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
CONDITIONS
Official Title
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of specified histologies
- Completed primary or interval debulking surgery
- Completed first-line platinum-based chemotherapy with stable disease, partial response, complete response, or no evidence of disease
- Provided tumor tissue that is not previously irradiated
- If HIV positive, well-controlled on antiretroviral therapy
- Undetectable hepatitis B viral load and received antiviral therapy if hepatitis B surface antigen positive
- Undetectable hepatitis C viral load if history of hepatitis C infection
You will not qualify if you...
- Has nonepithelial cancers, low-grade serous tumors, low-grade endometrioid tumors, borderline tumors, mucinous or seromucinous tumors predominantly mucinous, malignant Brenner's tumor, or undifferentiated carcinoma
- Known active central nervous system metastases or carcinomatous meningitis
- History of severe eye disease
- Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Uncontrolled significant cardiovascular or cerebrovascular disease
- History or current pneumonitis/interstitial lung disease requiring steroids
- Received prior systemic anticancer therapy other than first-line platinum-based chemotherapy
- Received live or live-attenuated vaccine within 30 days of randomization
- Known additional malignancy progressing or requiring treatment within past 3 years
- Active infection requiring systemic therapy
- Concurrent active hepatitis B and hepatitis C infections
- HIV infection with history of Kaposi's sarcoma or multicentric Castleman's disease
- Not recovered from major surgery or has ongoing surgical complications
- Homologous recombination deficiency positive, unknown, or inconclusive tumor status
- Active or ongoing stomatitis of any grade
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 41 locations
1
Mount Sinai Cancer Center ( Site 0029)
Miami Beach, Florida, United States, 33140
Actively Recruiting
2
Parkview Research Center at Parkview Regional Medical Center ( Site 0055)
Fort Wayne, Indiana, United States, 46845
Actively Recruiting
3
Women's Cancer Care ( Site 0018)
Covington, Louisiana, United States, 70433
Actively Recruiting
4
Nebraska Methodist Hospital ( Site 0004)
Omaha, Nebraska, United States, 68114
Actively Recruiting
5
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007)
Tulsa, Oklahoma, United States, 74146
Actively Recruiting
6
West Cancer Center and Research Institute ( Site 0013)
Germantown, Tennessee, United States, 38138
Actively Recruiting
7
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901)
Mar del Plata, Buenos Aires, Argentina, B7600FZO
Actively Recruiting
8
Sanatorio Parque - Oncología ( Site 2911)
Rosario, Santa Fe Province, Argentina, S2000DVC
Actively Recruiting
9
Instituto de Oncologia de Rosario ( Site 2909)
Rosario, Santa Fe Province, Argentina, S2000KZE
Actively Recruiting
10
Gallipoli Medical Research Ltd ( Site 0204)
Brisbane, Queensland, Australia, 4120
Actively Recruiting
11
Epworth Freemasons ( Site 0207)
East Melbourne, Victoria, Australia, 3002
Actively Recruiting
12
Aarhus Universitetshospital, Skejby ( Site 0903)
Aarhus, North Denmark, Denmark, 8200
Actively Recruiting
13
Kuopion Yliopistollinen Sairaala ( Site 1004)
Kuopio, Northern Savonia, Finland, 70200
Actively Recruiting
14
Tampereen yliopistollinen sairaala ( Site 1002)
Tampere, Pirkanmaa, Finland, 33520
Actively Recruiting
15
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001)
Turku, Southwest Finland, Finland, 20520
Actively Recruiting
16
Rambam Health Care Campus ( Site 1422)
Haifa, Israel, 3109601
Actively Recruiting
17
Edith Wolfson Medical Center ( Site 1423)
Holon, Israel, 5810001
Actively Recruiting
18
Gunma Prefectural Cancer Center ( Site 1605)
Ōta, Gunma, Japan, 373-8550
Actively Recruiting
19
Hokkaido University Hospital ( Site 1609)
Sapporo, Hokkaido, Japan, 060-8648
Actively Recruiting
20
Hyogo Cancer Center ( Site 1620)
Akashi, Hyōgo, Japan, 673-8558
Actively Recruiting
21
Iwate Medical University Hospital ( Site 1610)
Shiwa-gun, Iwate, Japan, 028-3695
Actively Recruiting
22
Saitama Medical University International Medical Center ( Site 1607)
Hidaka, Saitama, Japan, 350-1298
Actively Recruiting
23
Cancer Institute Hospital of JFCR ( Site 1614)
Koto, Tokyo, Japan, 135-8550
Actively Recruiting
24
Kagoshima City Hospital ( Site 1613)
Kagoshima, Japan, 890-8760
Actively Recruiting
25
Niigata Cancer Center Hospital ( Site 1608)
Niigata, Japan, 951-8566
Actively Recruiting
26
Stavanger Universitetssjukehus ( Site 2002)
Stavanger, Rogaland, Norway, 4068
Actively Recruiting
27
Oslo University Hospital ( Site 2001)
Oslo, Norway, 0424
Actively Recruiting
28
Severance Hospital ( Site 2302)
Seodaemun-Gu, Seoul, South Korea, 03722
Actively Recruiting
29
Keimyung University Dongsan Hospital ( Site 2304)
Daegu, Taegu-Kwangyokshi, South Korea, 42601
Actively Recruiting
30
Seoul National University Hospital ( Site 2301)
Seoul, South Korea, 03080
Actively Recruiting
31
Asan Medical Center ( Site 2305)
Seoul, South Korea, 05505
Actively Recruiting
32
Samsung Medical Center ( Site 2303)
Seoul, South Korea, 06351
Actively Recruiting
33
Inselspital Bern ( Site 3504)
Bern, Canton of Bern, Switzerland, 3010
Actively Recruiting
34
Ospedale Regionale Bellinzona e Valli ( Site 3501)
Bellinzona, Canton Ticino, Switzerland, 6500
Actively Recruiting
35
Kantonsspital Graubünden ( Site 3503)
Chur, Kanton Graubünden, Switzerland, 7000
Actively Recruiting
36
Hôpitaux Universitaires de Genève (HUG) ( Site 3502)
Geneva, Switzerland, 1205
Actively Recruiting
37
Taichung Veterans General Hospital ( Site 2603)
Taichung, Taiwan, 40705
Actively Recruiting
38
National Cheng Kung University Hospital ( Site 2602)
Tainan, Taiwan, 704302
Actively Recruiting
39
National Taiwan University Hospital ( Site 2601)
Taipei, Taiwan, 10002
Actively Recruiting
40
Mackay Memorial Hospital ( Site 2604)
Taipei, Taiwan, 104
Actively Recruiting
41
Linkou Chang Gung Memorial Hospital ( Site 2605)
Taoyuan, Taiwan, 333
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here